Filing Details
- Accession Number:
- 0001649094-24-000079
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-10-08 20:29:50
- Reporting Period:
- 2024-10-07
- Accepted Time:
- 2024-10-08 20:29:50
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1649094 | Vaxcyte Inc. | PCVX | Biological Products, (No Disgnostic Substances) (2836) | 464233385 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1918033 | Mikhail Eydelman | C/O Vaxcyte, Inc. 825 Industrial Road, Suite 300 San Carlos CA 94070 | Svp, Gen Counsel & Corp Sec | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-10-07 | 5,000 | $21.41 | 33,623 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-10-07 | 476 | $107.51 | 33,147 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-10-07 | 996 | $108.69 | 32,151 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-10-07 | 3,147 | $109.55 | 29,004 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-10-07 | 314 | $110.51 | 28,690 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-10-07 | 67 | $111.68 | 28,623 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2024-10-07 | 5,000 | $0.00 | 5,000 | $21.41 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
169,497 | 2032-05-08 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $107.08 to $107.77. The reporting person will provide upon request to the SEC, the issuer or security holder ofthe issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $108.085 to $109.05. The reporting person will provide upon request to the SEC, the issuer or security holder ofthe issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $109.18 to $110.15. The reporting person will provide upon request to the SEC, the issuer or security holder ofthe issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $110.235 to $111.12. The reporting person will provide upon request to the SEC, the issuer or security holder ofthe issuer, full information regarding the number of shares sold at each separate price.
- 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.